<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Heart J</journal-id><journal-id journal-id-type="publisher-id">eurheartj</journal-id><journal-id journal-id-type="hwp">ehj</journal-id><journal-title>European Heart Journal</journal-title><issn pub-type="ppub">0195-668X</issn><issn pub-type="epub">1522-9645</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19109245</article-id><article-id pub-id-type="pmc">2649285</article-id><article-id pub-id-type="doi">10.1093/eurheartj/ehn540</article-id><article-id pub-id-type="publisher-id">ehn540</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research</subject><subj-group><subject>Coronary Heart Disease</subject></subj-group></subj-group><series-title>Editor's Choice</series-title></article-categories><title-group><article-title>Improved Stratification of Autonomic Regulation for risk prediction in post-infarction patients with preserved left ventricular function (<italic>ISAR-Risk</italic>)</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bauer</surname><given-names>Axel</given-names></name><xref ref-type="aff" rid="af1">1</xref><xref ref-type="author-notes" rid="FN1">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Barthel</surname><given-names>Petra</given-names></name><xref ref-type="aff" rid="af1">1</xref><xref ref-type="author-notes" rid="FN1">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Schneider</surname><given-names>Raphael</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ulm</surname><given-names>Kurt</given-names></name><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>M&#x000fc;ller</surname><given-names>Alexander</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Joeinig</surname><given-names>Anke</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Stich</surname><given-names>Raphael</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kiviniemi</surname><given-names>Antti</given-names></name><xref ref-type="aff" rid="af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Hnatkova</surname><given-names>Katerina</given-names></name><xref ref-type="aff" rid="af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Huikuri</surname><given-names>Heikki</given-names></name><xref ref-type="aff" rid="af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Sch&#x000f6;mig</surname><given-names>Albert</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Malik</surname><given-names>Marek</given-names></name><xref ref-type="aff" rid="af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Schmidt</surname><given-names>Georg</given-names></name><xref ref-type="aff" rid="af1">1</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="af1"><label>1</label><addr-line>Medizinische Klinik und Deutsches Herzzentrum M&#x000fc;nchen der Technischen Universit&#x000e4;t M&#x000fc;nchen, Ismaninger Stra&#x000df;e 22, 81675 M&#x000fc;nchen</addr-line>, <country>Germany</country></aff><aff id="af2"><label>2</label><addr-line>Institut f&#x000fc;r Medizinische Statistik und Epidemiologie der Technischen Universit&#x000e4;t M&#x000fc;nchen, M&#x000fc;nchen</addr-line>, <country>Germany</country></aff><aff id="af3"><label>3</label><addr-line>Department of Medicine</addr-line>, <institution>University of Oulu</institution>, <addr-line>Oulu</addr-line>, <country>Finland</country></aff><aff id="af4"><label>4</label><addr-line>Division of Cardiac and Vascular Sciences</addr-line>, <institution>St George&#x02019;s, University of London</institution>, <addr-line>London</addr-line>, <country>UK</country></aff><author-notes><fn id="FN1"><label>&#x02020;</label><p>A.B. and P.B. contributed equally to this study.</p></fn><corresp id="cor1"><label>*</label>Corresponding author. Tel: <phone>+49 89 4140 2352</phone>, Fax: <fax>+49 89 4140 4862</fax>, Email: <email>gschmidt@tum.de</email></corresp></author-notes><pub-date pub-type="ppub"><month>3</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>23</day><month>12</month><year>2008</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>12</month><year>2008</year></pub-date><volume>30</volume><issue>5</issue><fpage>576</fpage><lpage>583</lpage><history><date date-type="received"><day>3</day><month>6</month><year>2008</year></date><date date-type="rev-recd"><day>10</day><month>11</month><year>2008</year></date><date date-type="accepted"><day>18</day><month>11</month><year>2008</year></date></history><copyright-statement>Published on behalf of the European Society of Cardiology. All rights reserved. &#x000a9; The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org</copyright-statement><copyright-year>2009</copyright-year><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/uk/"><p>The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org</p></license><abstract><sec><title>Aims</title><p>To investigate the combination of heart rate turbulence (HRT) and deceleration capacity (DC) as risk predictors in post-infarction patients with left ventricular ejection fraction (LVEF) &#x0003e; 30%.</p></sec><sec sec-type="methods"><title>Methods and results</title><p>We enrolled 2343 consecutive survivors of acute myocardial infarction (MI) (&#x0003c;76 years) in sinus rhythm. HRT and DC were obtained from 24 h Holter recordings. Patients with both abnormal HRT (slope &#x02264; 2.5 ms/RR and onset &#x02265; 0%) and abnormal DC (&#x02264;4.5 ms) were considered suffering from severe autonomic failure (SAF) and prospectively classified as high risk. Primary and secondary endpoints were all-cause, cardiac, and sudden cardiac mortality within the first 5 years of follow-up. During follow-up, 181 patients died; 39 deaths occurred in 120 patients with LVEF &#x02264; 30%, and 142 in 2223 patients with LVEF&#x0003e;30% (cumulative 5-year mortality rates of 37.9% and 7.8%, respectively). Among patients with LVEF &#x0003e; 30%, SAF identified another high-risk group of 117 patients with 37 deaths (cumulative 5-year mortality rates of 38.6% and 6.1%, respectively). Merging both high-risk groups (i.e. LVEF &#x02264; 30% and/or SAF) doubled the sensitivity of mortality prediction compared with LVEF &#x02264; 30% alone (21.1% vs. 42.1%, <italic>P</italic> &#x0003c; 0.001) while preserving 5-year mortality rate (38.2%).</p></sec><sec><title>Conclusion</title><p>In post-MI patients with LVEF&#x0003e;30%, SAF identifies a high-risk group equivalent in size and mortality risk to patients with LVEF &#x02264; 30%.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Autonomic function</kwd><kwd>Myocardial infarction</kwd><kwd>Risk stratification</kwd><kwd>Sudden death</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Reduction of mortality by implantable cardioverter-defibrillators (ICDs) has been well documented by several trials in cardiac patients with compromised left ventricular function assessed, as a rule, by low left ventricular ejection fraction (LVEF).<sup><xref ref-type="bibr" rid="EHN540C1">1</xref>&#x02013;<xref ref-type="bibr" rid="EHN540C5">5</xref></sup> Although the results of these studies have now been projected into standard clinical practice, a substantial problem remains because of the low sensitivity of the criterion of reduced LVEF.<sup><xref ref-type="bibr" rid="EHN540C6">6</xref>&#x02013;<xref ref-type="bibr" rid="EHN540C8">8</xref></sup> Many cardiac patients who die from sudden cardiac death, likely preventable by prophylactic ICD implantation, do not have left ventricular performance particularly compromised.<sup><xref ref-type="bibr" rid="EHN540C6">6</xref>,<xref ref-type="bibr" rid="EHN540C8">8</xref>&#x02013;<xref ref-type="bibr" rid="EHN540C10">10</xref></sup> According to current guidelines, these patients are considered as low risk patients and are not protected by intensive prophylactic treatment.<sup><xref ref-type="bibr" rid="EHN540C11">11</xref>,<xref ref-type="bibr" rid="EHN540C12">12</xref></sup> At present, methods for identification of high-risk patients without compromised LVEF are lacking. Consequently, prophylactic ICD implantation (or other prophylactic therapy) has never been tested in these patients. Hence, adequately potent risk stratification methods need to be first demonstrated in patients with preserved LVEF before any risk reduction prophylaxis can be attempted.</p><p>To address this need, we have conducted a large cohort follow-up study to investigate whether the assessment of abnormalities in cardiac autonomic function makes risk stratification feasible among patients without seriously compromised ventricular performance. To characterize abnormalities in cardiac autonomic function, we defined severe autonomic failure (SAF) as a combination of severely impaired baroreflex function with abnormal autonomic tone. For this purpose, we used Heart Rate Turbulence (HRT)<sup><xref ref-type="bibr" rid="EHN540C13">13</xref></sup> and cardiac Deceleration Capacity (DC).<sup><xref ref-type="bibr" rid="EHN540C14">14</xref></sup> Although the risk prediction power of these parameters was previously documented in independent patient populations, the ways of combining them have not been studied. In particular, previous studies suggested that DC might be more useful in identification of low-risk patients while the power of HRT is mainly in the selection of high-risk cases. This study therefore investigated the definition of high risk as the combination of mildly abnormal DC<sup><xref ref-type="bibr" rid="EHN540C14">14</xref></sup> (to exclude low-risk patients) with highly abnormal HRT<sup><xref ref-type="bibr" rid="EHN540C13">13</xref></sup> (to select high-risk patients).</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2a"><title>Study design, setting, and participants</title><p>Between January 1996 and March 2005, patients were enrolled into a prospective cohort study at two centres, namely the German Heart Centre and the Klinikum Rechts der Isar, both in Munich, Germany (see <italic>Figure&#x000a0;<xref ref-type="fig" rid="EHN540F1">1</xref></italic> for patient numbers). Eligible patients suffered from acute myocardial infarction (MI) no more than 4 weeks before enrolment, were not older than 75 years, presented in sinus rhythm, and did not meet the criteria for secondary therapy by implantable cardioverter-defibrillator (ICD)<sup><xref ref-type="bibr" rid="EHN540C11">11</xref></sup> before hospital discharge for the index MI. Of the 2343 study patients, 1455 were included in earlier investigations<sup><xref ref-type="bibr" rid="EHN540C7">7</xref>,<xref ref-type="bibr" rid="EHN540C14">14</xref></sup> and are reported here with extended follow-up (5 vs. 2 years). At the same time, the number of primary endpoints increased from 70 to 181.</p><fig id="EHN540F1" position="float"><label>Figure&#x000a0;1</label><caption><p>Flow chart of patient selection.</p></caption><graphic xlink:href="ehn54001"/></fig><p>MI was diagnosed if a patient had at least two of the following findings: chest pain for &#x02265;20 min, creatine kinase-MB above the doubled upper normal limit of our laboratory, and ST-segment elevation of &#x02265;0.1 mV in two or more limb leads or &#x02265;0.2 mV in two or more contiguous precordial leads at the time of admission. Diabetes mellitus was considered present either if a patient was diagnosed and was receiving treatment (diet, tablets, or insulin) or if a blood glucose concentration of &#x02265;11 mmol/L was found in repeated samples. The patients were followed up for a median of 4.9 years (2.8&#x02013;5.0 years). The local Ethics Committee approved the collection of data and analysis of Holter recordings. Since the data obtained were non-invasive and did not exceed usual clinical management of the patients, the local Ethics Committee decided that signed informed consent was not needed. However, we did obtain oral informed consent.</p></sec><sec id="s2b"><title>Assessment of autonomic markers</title><p>Each patient of the study population (<italic>n</italic> = 2343) underwent 24 h Holter recording. These recordings were obtained at a median of 8 days after the index infarction (interquartile range 5&#x02013;11 days). All recordings were routinely processed using standard commercial equipment (Oxford Excel Holter system, Oxford instruments; Pathfinder 700, Reynolds Medical; and Mortara Holter system, Mortara Instrument) to obtain the sequence of individual RR intervals together with the distinction of sinus rhythm beats and ventricular premature complexes. Using these sequences, HRT and DC were calculated using previously published technologies<sup><xref ref-type="bibr" rid="EHN540C13">13</xref>&#x02013;<xref ref-type="bibr" rid="EHN540C15">15</xref></sup> that are presently available as simple add-ons to standard modern Holter systems.</p><p>Briefly, HRT quantifies the physiological short-term oscillation of cardiac cycle lengths that follows spontaneous ventricular premature complexes.<sup><xref ref-type="bibr" rid="EHN540C16">16</xref></sup> HRT consists typically of a brief heart rate acceleration followed by a gradual heart rate deceleration. These HRT phases are quantified by two numerical descriptors, HRT onset and HRT slope. DC is an integral measure of all deceleration-related oscillation observed over 24 h. Computation of DC is based on a novel signal processing algorithm capable of extracting periodic components out of non-stationary biological signals.</p><p>Consistent with previous reports, HRT onset was considered abnormal if &#x02265;0%,<sup><xref ref-type="bibr" rid="EHN540C13">13</xref></sup> HRT slope if &#x02264;2.5 ms per RR interval,<sup><xref ref-type="bibr" rid="EHN540C13">13</xref></sup> and DC if &#x02264;4.5 ms.<sup><xref ref-type="bibr" rid="EHN540C14">14</xref></sup></p><p>Patients who exhibited these pathologies in both components of HRT as well as in DC were considered to suffer from seriously abnormal cardiac autonomic modulations. The term SAF was used to describe this abnormality.</p></sec><sec id="s2c"><title>Left ventricular performance</title><p>In each patient, LVEF was assessed by left ventricular angiography (<italic>n</italic> = 1686) or biplane echocardiography (<italic>n</italic> = 657) during the second week after the index infarction. In agreement with previous reports on the utilization of prophylactic ICDs in patients with compromised left ventricular performance,<sup><xref ref-type="bibr" rid="EHN540C3">3</xref>,<xref ref-type="bibr" rid="EHN540C11">11</xref></sup> reduced LVEF was defined if &#x02264;30%.</p></sec><sec id="s2d"><title>Endpoints of the study</title><p>Last planned follow-up assessment was 1/2007. In cases of death, the reason for death was verified from hospital and autopsy records, and from either the primary physician or those witnessing the death. An independent endpoint committee determined the mode of death. Deaths were categorized as cardiac and non-cardiac. Cardiac deaths were further categorized as sudden and non-sudden. Cardiac death was defined as sudden if it was<sup><xref ref-type="bibr" rid="EHN540C1">1</xref></sup> a witnessed death occurring within 60 min of the onset of new symptoms, unless there was an obvious non-cardiac cause,<sup><xref ref-type="bibr" rid="EHN540C2">2</xref></sup> an unwitnessed death within 24 h in the absence of pre-existing progressive circulatory failure or other causes of death, or<sup><xref ref-type="bibr" rid="EHN540C3">3</xref></sup> death during attempted resuscitation. The primary endpoint of the study was all-cause mortality within the first 5 years of follow-up; secondary endpoints were cardiac and sudden cardiac death also at 5 years of follow-up. The cut-off of 5 years was derived from the expected ICD longevity.</p></sec><sec id="s2e"><title>High-risk groups</title><p>Some patients who suffered from SAF also had LVEF &#x02264;30% which made them eligible for prophylactic ICD implantation based on the presently available criteria. Thus, to investigate what risk stratification by SAF offers in addition to reduced LVEF, we considered and compared two distinct high-risk groups, that is (i) patients with LVEF &#x02264;30% and (ii) patients with LVEF &#x0003e;30% and SAF. We also considered the group of all patients with SAF, and a combination of these high-risk groups, that is patients with either LVEF &#x02264;30% or LVEF &#x0003e;30% and SAF.</p></sec><sec id="s2f"><title>Statistics</title><p>Continuous variables are presented as median and inter-quartile range; qualitative data are expressed as absolute numbers and percentages. Comparison of variables between high-risk groups (LVEF &#x02264; 30% or SAF and LVEF &#x0003e; 30%) was performed with either a linear or logistic model in order to adjust for differences in age and sex. Survival curves for total mortality were estimated by the Kaplan&#x02013;Meier method<sup><xref ref-type="bibr" rid="EHN540C17">17</xref></sup> and compared using the two-sided log-rank test.<sup><xref ref-type="bibr" rid="EHN540C18">18</xref></sup> The influence of SAF on total mortality was estimated with the Cox proportional-hazards model adjusted for established risk factors, including age &#x02265;65years, presence of diabetes mellitus, history of previous MI, arrhythmia signs on Holter (&#x02265;10 VPCs/h and/or non-sustained ventricular tachycardia on Holter) and sex. Mortality rates of both high risks groups (LVEF &#x02264; 30% and SAF and LVEF &#x0003e; 30%) were also compared by the Cox-model adjusted for age and sex. The proportional hazard assumption of the various parameters was investigated by using Schoenfeld residuals. Hazard ratios together with 95% confidence limits were calculated. Secondary endpoints (cardiac death and sudden death) were analysed with competing risk models<sup><xref ref-type="bibr" rid="EHN540C19">19</xref></sup> and compared with the procedure proposed by Gray.<sup><xref ref-type="bibr" rid="EHN540C20">20</xref></sup> Differences were considered statistically significant, if <italic>P</italic> &#x0003c; 0.05. Sensitivity and specificity were calculated for the prediction of all-cause, cardiac, and sudden cardiac death in (i) patients with LVEF &#x02264;30%, (ii) patients with SAF, (iii) patients with SAF and LVEF &#x0003e;30%, and (iv) patients with either LVEF &#x02264; 30% or &#x0003e;30% and SAF (i.e. LVEF &#x02264; 30% and/or SAF).<sup><xref ref-type="bibr" rid="EHN540C21">21</xref></sup></p></sec><sec id="s2g"><title>Statement of responsibility</title><p>The authors had full access to the data and take responsibility for its integrity. All authors have read and agree to the manuscript as written.</p></sec></sec><sec id="s3"><title>Results</title><p>The clinical characteristics of recruited patients are shown in <italic>Table&#x000a0;<xref ref-type="table" rid="EHN540TB1">1</xref></italic>. Eighteen patients (i.e. 0.8% of the total population) were lost to follow-up. They were censored at the date of latest contact.</p><table-wrap id="EHN540TB1" position="float"><label>Table 1</label><caption><p>Characteristics of the study population (<italic>n</italic> = 2343)</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="(" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Characteristic</th><th rowspan="1" colspan="1"/></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age (years) (median, IQR)</td><td rowspan="1" colspan="1">59 (51&#x02013;67)</td></tr><tr><td rowspan="1" colspan="1">Female sex [<italic>n</italic> (%)]</td><td rowspan="1" colspan="1">456 (20)</td></tr><tr><td rowspan="1" colspan="1">Diabetes mellitus [<italic>n</italic> (%)]</td><td rowspan="1" colspan="1">412(18)</td></tr><tr><td rowspan="1" colspan="1">History of previous MI [<italic>n</italic> (%)]</td><td rowspan="1" colspan="1">261 (11)</td></tr><tr><td rowspan="1" colspan="1">CK<sub>max</sub> (U/L) (median, IQR)</td><td rowspan="1" colspan="1">1189 (598&#x02013;2460)</td></tr><tr><td rowspan="1" colspan="1">Creatinine (&#x000b5;mol/L) (median, IQR)</td><td rowspan="1" colspan="1">1.1 (1.0&#x02013;1.3)</td></tr><tr><td rowspan="1" colspan="1">LVEF (%)</td><td rowspan="1" colspan="1">55 (45&#x02013;62)</td></tr><tr><td rowspan="1" colspan="1">VPC (count/h) (median, IQR)</td><td rowspan="1" colspan="1">0.5 (0.1&#x02013;3.5)</td></tr><tr><td rowspan="1" colspan="1">Nonsustained VT [<italic>n</italic> (%)]</td><td rowspan="1" colspan="1">156 (7)</td></tr><tr><td rowspan="1" colspan="1">PCI [<italic>n</italic> (%)]</td><td rowspan="1" colspan="1">2159 (92)</td></tr><tr><td rowspan="1" colspan="1">Thrombolysis [<italic>n</italic> (%)]</td><td rowspan="1" colspan="1">62 (3)</td></tr><tr><td rowspan="1" colspan="1">CABG [<italic>n</italic> (%)]</td><td rowspan="1" colspan="1">39 (2)</td></tr><tr><td rowspan="1" colspan="1">Aspirin [<italic>n</italic> (%)]</td><td rowspan="1" colspan="1">2298 (98)</td></tr><tr><td rowspan="1" colspan="1">&#x003b2;-Blocker [<italic>n</italic> (%)]</td><td rowspan="1" colspan="1">2210 (94)</td></tr><tr><td rowspan="1" colspan="1">ACE inhibitors [<italic>n</italic> (%)]</td><td rowspan="1" colspan="1">2132 (91)</td></tr><tr><td rowspan="1" colspan="1">Statins [<italic>n</italic> (%)]</td><td rowspan="1" colspan="1">2057 (88)</td></tr><tr><td rowspan="1" colspan="1">Diuretics [<italic>n</italic> (%)]</td><td rowspan="1" colspan="1">926 (40)</td></tr></tbody></table><table-wrap-foot><fn><p>ACE, angiotensin-converting enzyme; CABG, coronary artery bypass graft; CK, creatine kinase; IQR, inter-quartile range; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention; VPC, ventricular premature complex; VT, ventricular tachycardia.</p></fn></table-wrap-foot></table-wrap><p>During the first 5 years of follow-up, 181 patients died (<italic>Table&#x000a0;<xref ref-type="table" rid="EHN540TB2">2</xref></italic>). Only 39 (22%) of these deaths occurred in patients with LVEF &#x02264;30% (<italic>n</italic> = 120; 5.1% of the total population) whereas 142 (78%) occurred in patients with LVEF &#x0003e; 30% (<italic>n</italic> = 2223; 94.9% of the total population). Cumulative mortality curves of patients stratified by LVEF &#x02264;30% are shown in the left panels of <italic>Figure&#x000a0;<xref ref-type="fig" rid="EHN540F2">2</xref></italic>. After 5 years, cumulative mortality rates of patients with LVEF &#x02264;30% and &#x0003e;30% were 37.9% and 7.8%, respectively (<italic>&#x003c7;</italic><sup>2</sup> = 110.1, <italic>P</italic> &#x0003c; 0.001).</p><fig id="EHN540F2" position="float"><label>Figure&#x000a0;2</label><caption><p>Kaplan&#x02013;Meier curves of all-cause mortality, cardiac mortality and sudden cardiac death for all patients (<italic>n</italic> = 2343) stratified by left ventricular ejection fraction (LVEF; left panels), for all patients (<italic>n</italic> = 2343) stratified by presence of severe autonomic failure (SAF; middle panels) and for patients with LVEF &#x0003e;30% (<italic>n</italic> = 2223) also stratified by presence of SAF (right panels). The number of patients of the individual groups involved in the analyses at 0, 1, 2, 3, 4, and 5 years are shown under the graphs (the same numbers apply to all three end-points). The top and the bottom row corresponds to the upper and bottom Kaplan&#x02013;Meier curve respectively.</p></caption><graphic xlink:href="ehn54002"/></fig><table-wrap id="EHN540TB2" position="float"><label>Table 2</label><caption><p>Endpoints at 5 years</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Group</th><th align="left" rowspan="1" colspan="1">Total</th><th align="left" rowspan="1" colspan="1">All-cause deaths</th><th align="left" rowspan="1" colspan="1">Cardiac deaths</th><th align="left" rowspan="1" colspan="1">Sudden cardiac deaths</th><th align="left" rowspan="1" colspan="1">Death not specified</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">LVEF &#x02264; 30%</td><td rowspan="1" colspan="1">120</td><td rowspan="1" colspan="1">39</td><td rowspan="1" colspan="1">29</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">SAF</td><td rowspan="1" colspan="1">152</td><td rowspan="1" colspan="1">52</td><td rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">LVEF &#x0003e; 30% and SAF</td><td rowspan="1" colspan="1">117</td><td rowspan="1" colspan="1">37</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">Others (=LVEF &#x0003e; 30% and no SAF)</td><td rowspan="1" colspan="1">2106</td><td rowspan="1" colspan="1">105</td><td rowspan="1" colspan="1">48</td><td rowspan="1" colspan="1">29</td><td rowspan="1" colspan="1">8</td></tr><tr><td rowspan="1" colspan="1">Total</td><td rowspan="1" colspan="1">2343</td><td rowspan="1" colspan="1">181</td><td rowspan="1" colspan="1">104</td><td rowspan="1" colspan="1">55</td><td rowspan="1" colspan="1">14</td></tr></tbody></table><table-wrap-foot><fn><p>LVEF left ventricular ejection fraction; SAF severe autonomic failure.</p></fn></table-wrap-foot></table-wrap><p>Among patients with LVEF &#x0003e;30%, SAF identified 117 cases (i.e. 5.0% of the total population) as high-risk patients, out of whom 37 died during the first 5 years of follow-up. Cumulative mortality curves of these patients are shown in the right panels of <italic>Figure&#x000a0;<xref ref-type="fig" rid="EHN540F2">2</xref></italic>. After 5 years of follow-up, cumulative mortality rates of patients with and without SAF were 38.6% and 6.1%, respectively (<italic>&#x003c7;</italic><sup>2</sup> = 134, <italic>P</italic> &#x0003c; 0.001). If one of the SAF components, i.e. either DC or HRT, was abnormal, the corresponding cumulative mortality rate was 9.5%; if neither component was abnormal, the cumulative mortality rate was 4.0%. On multivariable analysis (adjusted for age, presence of diabetes mellitus, history of previous MI, arrhythmia on Holter and sex), SAF yielded a hazard ratio of 4.6 [95% confidence interval (CI) 3.1&#x02013;7.0] (<italic>P</italic> &#x0003c; 0.001).</p><p>There was no significant difference between the mortality rates of both high-risk groups adjusted for age and sex (SAF and LVEF &#x0003e; 30% vs. LVEF &#x02264; 30%; hazard ratio of 0.83 (95% CI 0.52&#x02013;1.32). Similar figures were observed for cardiac death (relative risk = 0.88, 95% CI 0.51&#x02013;1.52) and sudden cardiac death (relative risk = 0.93, 95% CI 0.42&#x02013;2.08). Merging of the two high-risk groups, i.e. considering patients with either LVEF &#x02264; 30% or LVEF &#x0003e; 30% and SAF, led to an increase in sensitivity (<italic>Table&#x000a0;<xref ref-type="table" rid="EHN540TB3">3</xref></italic>), while maintaining a high 5-year mortality rate at 38.2%.</p><table-wrap id="EHN540TB3" position="float"><label>Table 3</label><caption><p>Positive and negative predictive accuracies, sensitivities and specificities for prediction of all-cause mortality, cardiac mortality, and sudden cardiac death by high-risk groups</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">LVEF &#x02264; 30%</th><th align="left" rowspan="1" colspan="1">SAF</th><th align="left" rowspan="1" colspan="1">SAF (in LVEF &#x0003e; 30%)</th><th align="left" rowspan="1" colspan="1">LVEF &#x02264; 30% or LVEF &#x0003e; 30% and SAF</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Total count</td><td rowspan="1" colspan="1">120</td><td rowspan="1" colspan="1">152</td><td rowspan="1" colspan="1">117</td><td rowspan="1" colspan="1">237</td></tr><tr><td colspan="5" rowspan="1"><hr/></td></tr><tr><td colspan="5" rowspan="1">Prediction of all-cause mortality at 5 years</td></tr><tr><td rowspan="1" colspan="1">&#x02003;All-cause deaths</td><td rowspan="1" colspan="1">39</td><td rowspan="1" colspan="1">52</td><td rowspan="1" colspan="1">37</td><td rowspan="1" colspan="1">76</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Positive predictive accuracy (%)</td><td rowspan="1" colspan="1">37.9</td><td rowspan="1" colspan="1">39.9</td><td rowspan="1" colspan="1">38.6</td><td rowspan="1" colspan="1">38.2</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Negative predictive accuracy (%)</td><td rowspan="1" colspan="1">92.2</td><td rowspan="1" colspan="1">92.8</td><td rowspan="1" colspan="1">93.9</td><td rowspan="1" colspan="1">93.9</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Sensitivity (%)</td><td rowspan="1" colspan="1">21.1</td><td rowspan="1" colspan="1">28.2</td><td rowspan="1" colspan="1">26.0</td><td rowspan="1" colspan="1">42.1</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Specificity (%)</td><td rowspan="1" colspan="1">96.5</td><td rowspan="1" colspan="1">95.7</td><td rowspan="1" colspan="1">96.5</td><td rowspan="1" colspan="1">93.1</td></tr><tr><td colspan="5" rowspan="1"><hr/></td></tr><tr><td colspan="5" rowspan="1">Prediction of cardiac mortality at 5 years</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Cardiac deaths</td><td rowspan="1" colspan="1">29</td><td rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">56</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Positive predictive accuracy (%)</td><td rowspan="1" colspan="1">27.6</td><td rowspan="1" colspan="1">29.9</td><td rowspan="1" colspan="1">27.1</td><td rowspan="1" colspan="1">27.3</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Negative predictive accuracy (%)</td><td rowspan="1" colspan="1">95.9</td><td rowspan="1" colspan="1">96.4</td><td rowspan="1" colspan="1">97.2</td><td rowspan="1" colspan="1">97.2</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Sensitivity (%)</td><td rowspan="1" colspan="1">27.1</td><td rowspan="1" colspan="1">37.2</td><td rowspan="1" colspan="1">34.8</td><td rowspan="1" colspan="1">52.9</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Specificity (%)</td><td rowspan="1" colspan="1">96.1</td><td rowspan="1" colspan="1">95.2</td><td rowspan="1" colspan="1">96.0</td><td rowspan="1" colspan="1">92.2</td></tr><tr><td colspan="5" rowspan="1"><hr/></td></tr><tr><td colspan="5" rowspan="1">Prediction of sudden cardiac death at 5 years</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Sudden cardiac deaths</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">26</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Positive predictive accuracy (%)</td><td rowspan="1" colspan="1">12.0</td><td rowspan="1" colspan="1">11.6</td><td rowspan="1" colspan="1">13.4</td><td rowspan="1" colspan="1">12.8</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Negative predictive accuracy (%)</td><td rowspan="1" colspan="1">97.7</td><td rowspan="1" colspan="1">97.8</td><td rowspan="1" colspan="1">98.3</td><td rowspan="1" colspan="1">98.3</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Sensitivity (%)</td><td rowspan="1" colspan="1">22.1</td><td rowspan="1" colspan="1">27.1</td><td rowspan="1" colspan="1">30.7</td><td rowspan="1" colspan="1">46.6</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Specificity (%)</td><td rowspan="1" colspan="1">95.4</td><td rowspan="1" colspan="1">94.1</td><td rowspan="1" colspan="1">95.3</td><td rowspan="1" colspan="1">90.9</td></tr></tbody></table><table-wrap-foot><fn><p>LVEF, left ventricular ejection fraction; SAF, severe autonomic failure.</p></fn></table-wrap-foot></table-wrap><p>Compared to patients with LVEF &#x02264; 30%, patients with SAF and LVEF &#x0003e; 30% were older (68 vs. 62 years) and more often of female sex (32% vs. 12%) (<italic>Table&#x000a0;<xref ref-type="table" rid="EHN540TB4">4</xref></italic>). After adjustment for age and sex statistically significant differences between both high-risk groups were observed for prescription of diuretics (61% vs. 83%) and creatine kinase (1.257 vs. 2.269 U/L).</p><table-wrap id="EHN540TB4" position="float"><label>Table 4</label><caption><p>Comparison of high-risk groups</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Characteristic</th><th align="left" rowspan="1" colspan="1">LVEF &#x02264; 30%</th><th align="left" rowspan="1" colspan="1">SAF and LVEF &#x0003e; 30%</th><th align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><italic>n</italic></td><td rowspan="1" colspan="1">120</td><td rowspan="1" colspan="1">117</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">LVEF (%) (median, IQR)</td><td rowspan="1" colspan="1">25 (21&#x02013;28)</td><td rowspan="1" colspan="1">46 (39&#x02013;56)</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Age (years) (median, IQR)</td><td rowspan="1" colspan="1">62 (55&#x02013;68)</td><td rowspan="1" colspan="1">68 (60&#x02013;72)</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Female sex [<italic>n</italic> (%)]</td><td rowspan="1" colspan="1">14 (12)</td><td rowspan="1" colspan="1">37 (32)</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td colspan="4" rowspan="1"><hr/></td></tr><tr><td colspan="4" rowspan="1"><italic>P</italic>-values adjusted for age and sex</td></tr><tr><td rowspan="1" colspan="1">Diabetes mellitus [<italic>n</italic> (%)]</td><td rowspan="1" colspan="1">26 (22)</td><td rowspan="1" colspan="1">37 (32)</td><td rowspan="1" colspan="1">0.349</td></tr><tr><td rowspan="1" colspan="1">History of previous MI [<italic>n</italic> (%)]</td><td rowspan="1" colspan="1">34 (28)</td><td rowspan="1" colspan="1">20 (17)</td><td rowspan="1" colspan="1">0.029</td></tr><tr><td rowspan="1" colspan="1">CK<sub>max</sub> (U/L) (median, IQR)</td><td rowspan="1" colspan="1">2269 (952&#x02013;5139)</td><td rowspan="1" colspan="1">1257 (510&#x02013;2455)</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">Creatinine (mg/dL) (median, IQR)</td><td rowspan="1" colspan="1">1.3 (1.1&#x02013;1.5)</td><td rowspan="1" colspan="1">1.2 (1.0&#x02013;1.4)</td><td rowspan="1" colspan="1">0.316</td></tr><tr><td rowspan="1" colspan="1">VPC (count/h) (median, IQR)</td><td rowspan="1" colspan="1">5 (1&#x02013;27)</td><td rowspan="1" colspan="1">7 (2&#x02013;40)</td><td rowspan="1" colspan="1">0.700</td></tr><tr><td rowspan="1" colspan="1">Non-sustained VT [<italic>n</italic> (%)]</td><td rowspan="1" colspan="1">22 (18)</td><td rowspan="1" colspan="1">18 (15)</td><td rowspan="1" colspan="1">0.748</td></tr><tr><td rowspan="1" colspan="1">Mean HR (bpm) (median, IQR)</td><td rowspan="1" colspan="1">73 (66&#x02013;82)</td><td rowspan="1" colspan="1">74 (68&#x02013;81)</td><td rowspan="1" colspan="1">0.140</td></tr><tr><td rowspan="1" colspan="1">SDNN (ms) (median, IQR)</td><td rowspan="1" colspan="1">66 (53&#x02013;85)</td><td rowspan="1" colspan="1">68 (55&#x02013;89)</td><td rowspan="1" colspan="1">0.606</td></tr><tr><td rowspan="1" colspan="1">PCI [<italic>n</italic> (%)]</td><td rowspan="1" colspan="1">110 (92)</td><td rowspan="1" colspan="1">103 (88)</td><td rowspan="1" colspan="1">0.523</td></tr><tr><td rowspan="1" colspan="1">Thrombolysis [<italic>n</italic> (%)]</td><td rowspan="1" colspan="1">1 (1)</td><td rowspan="1" colspan="1">2 (2)</td><td rowspan="1" colspan="1">0.685</td></tr><tr><td rowspan="1" colspan="1">CABG [<italic>n</italic> (%)]</td><td rowspan="1" colspan="1">5 (4)</td><td rowspan="1" colspan="1">3 (3)</td><td rowspan="1" colspan="1">0.445</td></tr><tr><td rowspan="1" colspan="1">Aspirin [<italic>n</italic> (%)]</td><td rowspan="1" colspan="1">113 (94)</td><td rowspan="1" colspan="1">113 (97)</td><td rowspan="1" colspan="1">0.503</td></tr><tr><td rowspan="1" colspan="1">&#x003b2;-Blocker [<italic>n</italic> (%)]</td><td rowspan="1" colspan="1">109 (91)</td><td rowspan="1" colspan="1">102 (87)</td><td rowspan="1" colspan="1">0.475</td></tr><tr><td rowspan="1" colspan="1">ACE inhibitors [<italic>n</italic> (%)]</td><td rowspan="1" colspan="1">109 (91)</td><td rowspan="1" colspan="1">108 (92)</td><td rowspan="1" colspan="1">0.694</td></tr><tr><td rowspan="1" colspan="1">Statins [<italic>n</italic> (%)]</td><td rowspan="1" colspan="1">93 (76)</td><td rowspan="1" colspan="1">91 (78)</td><td rowspan="1" colspan="1">0.751</td></tr><tr><td rowspan="1" colspan="1">Diuretics [<italic>n</italic> (%)]</td><td rowspan="1" colspan="1">100 (83)</td><td rowspan="1" colspan="1">71 (61)</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="1" colspan="1">ICD implantation [<italic>n</italic> (%)]</td><td rowspan="1" colspan="1">20 (17)</td><td rowspan="1" colspan="1">6 (5)</td><td rowspan="1" colspan="1">0.013</td></tr><tr><td rowspan="1" colspan="1">ICD therapy in patients who survived follow-up [<italic>n</italic> (%)]</td><td rowspan="1" colspan="1">5 (4)</td><td rowspan="1" colspan="1">1(1)</td><td rowspan="1" colspan="1">0.166</td></tr></tbody></table><table-wrap-foot><fn><p>ACE, angiotensin-converting enzyme; CABG, coronary artery bypass graft; CK, creatine kinase; HR, heart rate; IQR, inter-quartile range; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention; VPC, ventricular premature complex; VT, ventricular tachycardia.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s4"><title>Discussion</title><p>In this population, SAF identifies high-risk post-MI patients among those with LVEF &#x0003e;30%. The size and risk-profile of the group of patients with LVEF&#x0003e;30% and SAF are practically identical to those of the high-risk group defined by reduced LVEF. This is not only true for total mortality but also for cardiac and sudden cardiac mortality.</p><p>Although risk stratification based purely on LVEF identified only approximately one-quarter of the patients who died during follow-up, combination of LVEF &#x02264; 30% with LVEF &#x0003e; 30% and SAF identified approximately one-half of them. At the same time, specificity was unaffected. It is thus likely that prophylactic ICD treatment in patients with LVEF &#x0003e; 30% and SAF would be no less efficacious than in patients with LVEF &#x02264; 30%. ICD therapy might actually be even more effective in patients with LVEF &#x0003e; 30% and SAF since these patients are less prone to deaths from pump failure which restricts the benefit offered by ICD.<sup><xref ref-type="bibr" rid="EHN540C22">22</xref>,<xref ref-type="bibr" rid="EHN540C23">23</xref></sup></p><p>There are good reasons to combine DC with HRT when defining SAF. Although both these parameters reflect cardiac autonomic modulations, HRT expresses reflex reaction to the cardiac rhythm to distinct disturbance by isolated ventricular premature beat.<sup><xref ref-type="bibr" rid="EHN540C13">13</xref>,<xref ref-type="bibr" rid="EHN540C24">24</xref>,<xref ref-type="bibr" rid="EHN540C25">25</xref></sup> On the contrary, DC integrates all the regulatory processes that slow heart rate on a beat-to-beat basis thus expressing an overall status of the autonomic, predominantly vagal balance.<sup><xref ref-type="bibr" rid="EHN540C14">14</xref>,<xref ref-type="bibr" rid="EHN540C15">15</xref></sup> Both these facets of autonomic assessment are reasonably independent each of the other which facilitates making their combination such a strong risk predictor. (Note the difference between cumulative mortality rates of 38.6% and 9.5% when both HRT and DC were abnormal, and when only one factor was abnormal, respectively.).</p><p>A number of other risk factors have been reported to differentiate between high- and low-risk survivors of MI independently of LVEF (e.g. heart-rate profile of post-exercise recovery,<sup><xref ref-type="bibr" rid="EHN540C26">26</xref>,<xref ref-type="bibr" rid="EHN540C27">27</xref></sup> nonlinear dynamics, detrended fluctuation analysis,<sup><xref ref-type="bibr" rid="EHN540C28">28</xref></sup> T wave alternans,<sup><xref ref-type="bibr" rid="EHN540C29">29</xref>&#x02013;<xref ref-type="bibr" rid="EHN540C32">32</xref></sup> electrophysiological testing,<sup><xref ref-type="bibr" rid="EHN540C33">33</xref>,<xref ref-type="bibr" rid="EHN540C34">34</xref></sup> etc.). With some of these factors, however, the reported sensitivities and specificities among patients with preserved LVEF are rather low. Other reported risk factors appear more viable. For instance, similar data to our findings were reported with T wave alternans (although with a smaller population and fewer events).<sup><xref ref-type="bibr" rid="EHN540C35">35</xref></sup> Possibly, combinations of T wave alternans with HRT and DC would improve risk prediction in this population even further.<sup><xref ref-type="bibr" rid="EHN540C36">36</xref></sup></p><p>Moreover, in contrast to the other techniques,<sup><xref ref-type="bibr" rid="EHN540C37">37</xref></sup> SAF assessment requires only a Holter recording to be obtained in post-infarction patients and is thus not limited only to patients who tolerate a specific provocative investigation (e.g. patients who can exercise for the assessment of T wave alternans and/or post-exercise heart rate recovery).</p><p>The clinical efficacy of ICD implantation in patients with LVEF &#x0003e; 30% and SAF needs to be prospectively tested. Since the incidence and mortality rates are equal to those in patients with LVEF &#x02264; 30% in whom successful ICD trials exist,<sup><xref ref-type="bibr" rid="EHN540C1">1</xref>&#x02013;<xref ref-type="bibr" rid="EHN540C3">3</xref></sup> such prospective studies appear fully viable.</p><p>The cumulative mortality of patients with SAF and LVEF &#x0003e; 30% constantly increased over the observation period and did not saturate. In other words, patients with LVEF &#x0003e; 30% and SAF continue to be at increased risk even if surviving the first years after MI. Thus, these patients would probably benefit from ICD prophylaxis even late after MI.</p><p>Intentionally, we did not compare primarily patients with LVEF &#x02264; 30% with all patients with SAF. Those patients who have both compromised LVEF and SAF are eligible for prophylactic ICD implantation according to present guidelines and we are not suggesting that SAF should compete with these guidelines. (In our population, we have not found any practically viable criterion that would allow excluding patients with LVEF&#x02264;30% from ICD prophylaxis&#x02014;data not presented here.) Rather, we show that SAF identifies a group with considerable high risk among those patients who are not covered by present guidelines on primary ICD prophylaxis.</p><p>The strong predictive power of SAF was confirmed by further analyses the details of which are beyond the scope of this text. Among others, while a number of conventional measures of heart-rate variability (HRV) were significant predictors of mortality, SAF yielded the strongest relative risk both uni- and multivariably independent of the cut-off values of conventional HRV measures. Also, the SAF components, i.e. HRT and DC were significant and independent multivariable predictors.</p><p>Several limitations of our study need to be recognized. We enrolled patients younger than 76 years. Therefore, our findings cannot be extrapolated to older post-infarction patients. Moreover, SAF assessment is restricted to patients presenting in sinus rhythm and thus not applicable for instance to patients with atrial fibrillation which is known to be associated with increased mortality risk including risk of sudden death.<sup><xref ref-type="bibr" rid="EHN540C38">38</xref></sup> Holter recordings were obtained at median of 8 days after index infarction which might trigger a question of reproducibility. Nevertheless, previous publications on HRT<sup><xref ref-type="bibr" rid="EHN540C13">13</xref>,<xref ref-type="bibr" rid="EHN540C39">39</xref>,<xref ref-type="bibr" rid="EHN540C40">40</xref></sup> and DC<sup><xref ref-type="bibr" rid="EHN540C14">14</xref></sup> showed that the power of SAF components was maintained also in populations that collected post-infarction Holter recordings at different times. Our enrolment spanned almost 10 years during which some advances in acute treatment have been made. More detailed analysis of our data (not presented here) does not show any differences in these findings between earlier and later parts of the population. Since it is difficult to distinguish between life saving ICD therapy and other ICD interventions, we did not include ICD therapy into study endpoints. As seen in <italic>Table&#x000a0;<xref ref-type="table" rid="EHN540TB4">4</xref></italic>, the numbers of patients with effective ICD therapy were small (only 4% of patients with LVEF &#x02264;30% experienced ICD therapy while surviving the follow-up) and including the ICD interventions into endpoints (analysis not presented here) did not change the principal results. The threshold of LVEF &#x02264; 30% and &#x0003e;30% was prospectively selected when designing this study. However, the results are not dependent on this selection. When re-analysing the data for high-risk groups of LVEF &#x02264;35% vs. &#x0003e;35% and SAF, the results were practically identical. A fraction of the data in our study was included in earlier investigations.<sup><xref ref-type="bibr" rid="EHN540C7">7</xref>,<xref ref-type="bibr" rid="EHN540C14">14</xref></sup> However, the present study is based on much larger data collection with substantially increased follow-up period in which the number of endpoints was more than doubled. To test the consistency of our data, we analysed the previously used and the new data separately and confirmed that the results are fully independent of the original publications (analysis not presented here). Finally, although cohort studies of this kind characterize risk groups, they cannot replace intervention trials.</p><p>In spite of these limitations, the results of our cohort study are sufficiently robust to indicate that the autonomic markers should be strongly considered in future cardiac prophylaxis. Assessment of SAF after acute MI is presently readily available.</p></sec><sec id="s5"><title>Supplementary material</title><p><ext-link ext-link-type="uri" xlink:href="http://eurheartj.oxfordjournals.org/cgi/content/full/ehn540/DC1">Supplementary material is available at <italic>European Heart Journal</italic> online</ext-link>.</p></sec><sec id="s6"><title>Funding</title><p>Grants from the <grant-sponsor>Bundesministerium f&#x000fc;r Bildung, Wissenschaft, Forschung und Technologie</grant-sponsor> (<grant-num>13 N/7073/7</grant-num>), <grant-sponsor>the Kommission f&#x000fc;r Klinische Forschung</grant-sponsor>, and <grant-sponsor>the Deutsche Forschungsgemeinschaft</grant-sponsor> (SFB 386). Funding to Pay the Open Access Charge was provided by GS.</p><p><bold>Conflict of interest:</bold> G.S. holds patents on Heart Rate Turbulence and Deceleration Capacity; both licensed to GE Healthcare and Medtronic. None of the other authors have any conflict of interest.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="PMC_1" content-type="local-data"><caption><title>[Supplementary Data]</title></caption><media mimetype="text" mime-subtype="html" xlink:href="ehn540_index.html"/><media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="ehn540_1.pdf"/></supplementary-material></sec></body><back><ack><title>Acknowledgement</title><p>Author contributions: Study concept and design by G.S., P.B., A.B., and A.S., acquisition of the data by P.B., A.B., A.J., and R.S.; processing of Holter recordings and SAF assessment by R.S., A.B., and A.M.; analysis and interpretation of the data by G.S., M.M., A.B., and P.B.; statistical analysis by K.U.; validation of SAF in the St George&#x02019;s Hospital Medical School Post-Infarction survey and EMIAT (presented as <ext-link ext-link-type="uri" xlink:href="http://eurheartj.oxfordjournals.org/cgi/content/full/ehn540/DC1">Supplementary material</ext-link>) by K.H. and M.M.; validation of SAF in MRFAT (presented as <ext-link ext-link-type="uri" xlink:href="http://eurheartj.oxfordjournals.org/cgi/content/full/ehn540/DC1">Supplementary material</ext-link>) by A.K. and H.H.; main composition of the manuscript by G.S., A.B., and M.M.; critical revisions by all co-authors. Final approval by all authors. Other contributions: we are thankful to the members of the independent endpoint and event committee: Drs Isabel Deisenhofer, Roland Schmidt, and Martin Karch of German Heart Centre Munich. We are also thankful to Elisbeth Arnoldi for involvement in collection of follow-up information.</p></ack><ref-list><title>References</title><ref id="EHN540C1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moss</surname><given-names>AJ</given-names></name><name><surname>Hall</surname><given-names>WJ</given-names></name><name><surname>Cannom</surname><given-names>DS</given-names></name><name><surname>Daubert</surname><given-names>JP</given-names></name><name><surname>Higgins</surname><given-names>SL</given-names></name><name><surname>Klein</surname><given-names>H</given-names></name><name><surname>Levine</surname><given-names>JH</given-names></name><name><surname>Saksena</surname><given-names>S</given-names></name><name><surname>Waldo</surname><given-names>AL</given-names></name><name><surname>Wilber</surname><given-names>D</given-names></name><name><surname>Brown</surname><given-names>MW</given-names></name><name><surname>Heo</surname><given-names>M</given-names></name></person-group><article-title>Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators</article-title><source>N Engl J Med</source><year>1996</year><volume>335</volume><fpage>1933</fpage><lpage>1940</lpage><pub-id pub-id-type="pmid">8960472</pub-id></citation></ref><ref id="EHN540C2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buxton</surname><given-names>AE</given-names></name><name><surname>Lee</surname><given-names>KL</given-names></name><name><surname>Fisher</surname><given-names>JD</given-names></name><name><surname>Josephson</surname><given-names>ME</given-names></name><name><surname>Prystowsky</surname><given-names>EN</given-names></name><name><surname>Hafley</surname><given-names>G</given-names></name></person-group><article-title>A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators</article-title><source>N Engl J Med</source><year>1999</year><volume>341</volume><fpage>1882</fpage><lpage>1890</lpage><pub-id pub-id-type="pmid">10601507</pub-id></citation></ref><ref id="EHN540C3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moss</surname><given-names>AJ</given-names></name><name><surname>Zareba</surname><given-names>W</given-names></name><name><surname>Hall</surname><given-names>WJ</given-names></name><name><surname>Klein</surname><given-names>H</given-names></name><name><surname>Wilber</surname><given-names>DJ</given-names></name><name><surname>Cannom</surname><given-names>DS</given-names></name><name><surname>Daubert</surname><given-names>JP</given-names></name><name><surname>Higgins</surname><given-names>SL</given-names></name><name><surname>Brown</surname><given-names>MW</given-names></name><name><surname>Andrews</surname><given-names>ML</given-names></name></person-group><article-title>Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction</article-title><source>N Engl J Med</source><year>2002</year><volume>346</volume><fpage>877</fpage><lpage>883</lpage><pub-id pub-id-type="pmid">11907286</pub-id></citation></ref><ref id="EHN540C4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bristow</surname><given-names>MR</given-names></name><name><surname>Saxon</surname><given-names>LA</given-names></name><name><surname>Boehmer</surname><given-names>J</given-names></name><name><surname>Krueger</surname><given-names>S</given-names></name><name><surname>Kass</surname><given-names>DA</given-names></name><name><surname>De Marco</surname><given-names>T</given-names></name><name><surname>Carson</surname><given-names>P</given-names></name><name><surname>DiCarlo</surname><given-names>L</given-names></name><name><surname>DeMets</surname><given-names>D</given-names></name><name><surname>White</surname><given-names>BG</given-names></name><name><surname>DeVries</surname><given-names>DW</given-names></name><name><surname>Feldman</surname><given-names>AM</given-names></name></person-group><article-title>Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure</article-title><source>N Engl J Med</source><year>2004</year><volume>350</volume><fpage>2140</fpage><lpage>2150</lpage><pub-id pub-id-type="pmid">15152059</pub-id></citation></ref><ref id="EHN540C5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bardy</surname><given-names>GH</given-names></name><name><surname>Lee</surname><given-names>KL</given-names></name><name><surname>Mark</surname><given-names>DB</given-names></name><name><surname>Poole</surname><given-names>JE</given-names></name><name><surname>Packer</surname><given-names>DL</given-names></name><name><surname>Boineau</surname><given-names>R</given-names></name><name><surname>Domanski</surname><given-names>M</given-names></name><name><surname>Troutman</surname><given-names>C</given-names></name><name><surname>Anderson</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>G</given-names></name><name><surname>McNulty</surname><given-names>SE</given-names></name><name><surname>Clapp-Channing</surname><given-names>N</given-names></name><name><surname>Davidson-Ray</surname><given-names>LD</given-names></name><name><surname>Fraulo</surname><given-names>ES</given-names></name><name><surname>Fishbein</surname><given-names>DP</given-names></name><name><surname>Luceri</surname><given-names>RM</given-names></name><name><surname>Ip</surname><given-names>JH</given-names></name></person-group><article-title>Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><fpage>225</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">15659722</pub-id></citation></ref><ref id="EHN540C6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huikuri</surname><given-names>HV</given-names></name><name><surname>Castellanos</surname><given-names>A</given-names></name><name><surname>Myerburg</surname><given-names>RJ</given-names></name></person-group><article-title>Sudden death due to cardiac arrhythmias</article-title><source>N Engl J Med</source><year>2001</year><volume>345</volume><fpage>1473</fpage><lpage>1482</lpage><pub-id pub-id-type="pmid">11794197</pub-id></citation></ref><ref id="EHN540C7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barthel</surname><given-names>P</given-names></name><name><surname>Schneider</surname><given-names>R</given-names></name><name><surname>Bauer</surname><given-names>A</given-names></name><name><surname>Ulm</surname><given-names>K</given-names></name><name><surname>Schmitt</surname><given-names>C</given-names></name><name><surname>Schomig</surname><given-names>A</given-names></name><name><surname>Schmidt</surname><given-names>G</given-names></name></person-group><article-title>Risk stratification after acute myocardial infarction by heart rate turbulence</article-title><source>Circulation</source><year>2003</year><volume>108</volume><fpage>1221</fpage><lpage>1226</lpage><pub-id pub-id-type="pmid">12939209</pub-id></citation></ref><ref id="EHN540C8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buxton</surname><given-names>AE</given-names></name></person-group><article-title>Risk stratification for sudden death: do we need anything more than ejection fraction?</article-title><source>Card Electrophysiol Rev</source><year>2003</year><volume>7</volume><fpage>434</fpage><lpage>437</lpage><pub-id pub-id-type="pmid">15071270</pub-id></citation></ref><ref id="EHN540C9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Myerburg</surname><given-names>RJ</given-names></name><name><surname>Interian</surname><given-names>A</given-names><suffix>Jr</suffix></name><name><surname>Mitrani</surname><given-names>RM</given-names></name><name><surname>Kessler</surname><given-names>KM</given-names></name><name><surname>Castellanos</surname><given-names>A</given-names></name></person-group><article-title>Frequency of sudden cardiac death and profiles of risk</article-title><source>Am J Cardiol</source><year>1997</year><volume>80</volume><fpage>10F</fpage><lpage>19F</lpage></citation></ref><ref id="EHN540C10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Myerburg</surname><given-names>RJ</given-names></name><name><surname>Mitrani</surname><given-names>R</given-names></name><name><surname>Interian</surname><given-names>A</given-names><suffix>Jr</suffix></name><name><surname>Castellanos</surname><given-names>A</given-names></name></person-group><article-title>Interpretation of outcomes of antiarrhythmic clinical trials: design features and population impact</article-title><source>Circulation</source><year>1998</year><volume>97</volume><fpage>1514</fpage><lpage>1521</lpage><pub-id pub-id-type="pmid">9576433</pub-id></citation></ref><ref id="EHN540C11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gregoratos</surname><given-names>G</given-names></name><name><surname>Abrams</surname><given-names>J</given-names></name><name><surname>Epstein</surname><given-names>AE</given-names></name><name><surname>Freedman</surname><given-names>RA</given-names></name><name><surname>Hayes</surname><given-names>DL</given-names></name><name><surname>Hlatky</surname><given-names>MA</given-names></name><name><surname>Kerber</surname><given-names>RE</given-names></name><name><surname>Naccarelli</surname><given-names>GV</given-names></name><name><surname>Schoenfeld</surname><given-names>MH</given-names></name><name><surname>Silka</surname><given-names>MJ</given-names></name><name><surname>Winters</surname><given-names>SL</given-names></name><name><surname>Gibbons</surname><given-names>RJ</given-names></name><name><surname>Antman</surname><given-names>EM</given-names></name><name><surname>Alpert</surname><given-names>JS</given-names></name><name><surname>Gregoratos</surname><given-names>G</given-names></name><name><surname>Hiratzka</surname><given-names>LF</given-names></name><name><surname>Faxon</surname><given-names>DP</given-names></name><name><surname>Jacobs</surname><given-names>AK</given-names></name><name><surname>Fuster</surname><given-names>V</given-names></name><name><surname>Smith</surname><given-names>SC</given-names><suffix>Jr</suffix></name></person-group><article-title>ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines)</article-title><source>Circulation</source><year>2002</year><volume>106</volume><fpage>2145</fpage><lpage>2161</lpage><pub-id pub-id-type="pmid">12379588</pub-id></citation></ref><ref id="EHN540C12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zipes</surname><given-names>DP</given-names></name><name><surname>Camm</surname><given-names>AJ</given-names></name><name><surname>Borggrefe</surname><given-names>M</given-names></name><name><surname>Buxton</surname><given-names>AE</given-names></name><name><surname>Chaitman</surname><given-names>B</given-names></name><name><surname>Fromer</surname><given-names>M</given-names></name><name><surname>Gregoratos</surname><given-names>G</given-names></name><name><surname>Klein</surname><given-names>G</given-names></name><name><surname>Moss</surname><given-names>AJ</given-names></name><name><surname>Myerburg</surname><given-names>RJ</given-names></name><name><surname>Priori</surname><given-names>SG</given-names></name><name><surname>Quinones</surname><given-names>MA</given-names></name><name><surname>Roden</surname><given-names>DM</given-names></name><name><surname>Silka</surname><given-names>MJ</given-names></name><name><surname>Tracy</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>SC</given-names><suffix>Jr</suffix></name><name><surname>Jacobs</surname><given-names>AK</given-names></name><name><surname>Adams</surname><given-names>CD</given-names></name><name><surname>Antman</surname><given-names>EM</given-names></name><name><surname>Anderson</surname><given-names>JL</given-names></name><name><surname>Hunt</surname><given-names>SA</given-names></name><name><surname>Halperin</surname><given-names>JL</given-names></name><name><surname>Nishimura</surname><given-names>R</given-names></name><name><surname>Ornato</surname><given-names>JP</given-names></name><name><surname>Page</surname><given-names>RL</given-names></name><name><surname>Riegel</surname><given-names>B</given-names></name><name><surname>Blanc</surname><given-names>JJ</given-names></name><name><surname>Budaj</surname><given-names>A</given-names></name><name><surname>Dean</surname><given-names>V</given-names></name><name><surname>Deckers</surname><given-names>JW</given-names></name><name><surname>Despres</surname><given-names>C</given-names></name><name><surname>Dickstein</surname><given-names>K</given-names></name><name><surname>Lekakis</surname><given-names>J</given-names></name><name><surname>McGregor</surname><given-names>K</given-names></name><name><surname>Metra</surname><given-names>M</given-names></name><name><surname>Morais</surname><given-names>J</given-names></name><name><surname>Osterspey</surname><given-names>A</given-names></name><name><surname>Tamargo</surname><given-names>JL</given-names></name><name><surname>Zamorano</surname><given-names>JL</given-names></name></person-group><article-title>ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society</article-title><source>Circulation</source><year>2006</year><volume>114</volume><fpage>e385</fpage><lpage>e484</lpage><pub-id pub-id-type="pmid">16935995</pub-id></citation></ref><ref id="EHN540C13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>G</given-names></name><name><surname>Malik</surname><given-names>M</given-names></name><name><surname>Barthel</surname><given-names>P</given-names></name><name><surname>Schneider</surname><given-names>R</given-names></name><name><surname>Ulm</surname><given-names>K</given-names></name><name><surname>Rolnitzky</surname><given-names>L</given-names></name><name><surname>Camm</surname><given-names>AJ</given-names></name><name><surname>Bigger</surname><given-names>JT</given-names><suffix>Jr</suffix></name><name><surname>Schomig</surname><given-names>A</given-names></name></person-group><article-title>Heart-rate turbulence after ventricular premature beats as a predictor of mortality after acute myocardial infarction</article-title><source>Lancet</source><year>1999</year><volume>353</volume><fpage>1390</fpage><lpage>1396</lpage><pub-id pub-id-type="pmid">10227219</pub-id></citation></ref><ref id="EHN540C14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>A</given-names></name><name><surname>Kantelhardt</surname><given-names>JW</given-names></name><name><surname>Barthel</surname><given-names>P</given-names></name><name><surname>Schneider</surname><given-names>R</given-names></name><name><surname>Makikallio</surname><given-names>T</given-names></name><name><surname>Ulm</surname><given-names>K</given-names></name><name><surname>Hnatkova</surname><given-names>K</given-names></name><name><surname>Schomig</surname><given-names>A</given-names></name><name><surname>Huikuri</surname><given-names>H</given-names></name><name><surname>Bunde</surname><given-names>A</given-names></name><name><surname>Malik</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>G</given-names></name></person-group><article-title>Deceleration capacity of heart rate as a predictor of mortality after myocardial infarction: cohort study</article-title><source>Lancet</source><year>2006</year><volume>367</volume><fpage>1674</fpage><lpage>1681</lpage><pub-id pub-id-type="pmid">16714188</pub-id></citation></ref><ref id="EHN540C15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>A</given-names></name><name><surname>Kantelhardt</surname><given-names>JW</given-names></name><name><surname>Bunde</surname><given-names>A</given-names></name><name><surname>Malik</surname><given-names>M</given-names></name><name><surname>Schneider</surname><given-names>R</given-names></name><name><surname>Schmidt</surname><given-names>G</given-names></name></person-group><article-title>Phase-rectified signal averaging detects quasi-periodicities in non-stationary data</article-title><source>Physica A</source><year>2006</year><volume>364</volume><fpage>423</fpage><lpage>434</lpage></citation></ref><ref id="EHN540C16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>A</given-names></name><name><surname>Malik</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>G</given-names></name><name><surname>Barthel</surname><given-names>P</given-names></name><name><surname>Bonnemeier</surname><given-names>H</given-names></name><name><surname>Cygankiewicz</surname><given-names>I</given-names></name><name><surname>Guzik</surname><given-names>P</given-names></name><name><surname>Lombardi</surname><given-names>F</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>A</given-names></name><name><surname>Oto</surname><given-names>A</given-names></name><name><surname>Schneider</surname><given-names>R</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Wichterle</surname><given-names>D</given-names></name><name><surname>Zareba</surname><given-names>W</given-names></name></person-group><article-title>Heart rate turbulence: standards of measurement, physiological interpretation, and clinical use (ISHNE Consensus)</article-title><source>J Am Coll Cardiol</source><year>2008</year><volume>52</volume><fpage>1353</fpage><lpage>1365</lpage><pub-id pub-id-type="pmid">18940523</pub-id></citation></ref><ref id="EHN540C17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>E</given-names></name><name><surname>Meier</surname><given-names>P</given-names></name></person-group><article-title>Nonparametric estimation from incomplete observations</article-title><source>J Am Stat Ass</source><year>1958</year><volume>53</volume><fpage>457</fpage><lpage>481</lpage></citation></ref><ref id="EHN540C18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peto</surname><given-names>R</given-names></name><name><surname>Peto</surname><given-names>J</given-names></name></person-group><article-title>Asymptotically efficient rank invariant test procedures</article-title><source>J R Stat Soc</source><year>1972</year><volume>A135</volume><fpage>185</fpage><lpage>198</lpage></citation></ref><ref id="EHN540C19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gooley</surname><given-names>TA</given-names></name><name><surname>Leisenring</surname><given-names>W</given-names></name><name><surname>Crowley</surname><given-names>J</given-names></name><name><surname>Storer</surname><given-names>BE</given-names></name></person-group><article-title>Estimation of failure probabilities in the presence of competing risks: new representations of old estimators</article-title><source>Stat Med</source><year>1999</year><volume>18</volume><fpage>695</fpage><lpage>706</lpage><pub-id pub-id-type="pmid">10204198</pub-id></citation></ref><ref id="EHN540C20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>RJ</given-names></name></person-group><article-title>A class of k-sample tests for comparing the cumulative incidence of a competing risk</article-title><source>Ann Stat</source><year>1988</year><volume>16</volume><fpage>1141</fpage><lpage>1154</lpage></citation></ref><ref id="EHN540C21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heagerty</surname><given-names>P</given-names></name><name><surname>Lumley</surname><given-names>T</given-names></name><name><surname>Pepe</surname><given-names>M</given-names></name></person-group><article-title>Time-dependent ROC curves for censored survival data and a diagnostic marker</article-title><source>Biometrics</source><year>2000</year><volume>56</volume><fpage>337</fpage><lpage>344</lpage><pub-id pub-id-type="pmid">10877287</pub-id></citation></ref><ref id="EHN540C22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hohnloser</surname><given-names>SH</given-names></name><name><surname>Kuck</surname><given-names>KH</given-names></name><name><surname>Dorian</surname><given-names>P</given-names></name><name><surname>Roberts</surname><given-names>RS</given-names></name><name><surname>Hampton</surname><given-names>JR</given-names></name><name><surname>Hatala</surname><given-names>R</given-names></name><name><surname>Fain</surname><given-names>E</given-names></name><name><surname>Gent</surname><given-names>M</given-names></name><name><surname>Connolly</surname><given-names>SJ</given-names></name></person-group><article-title>Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction</article-title><source>N Engl J Med</source><year>2004</year><volume>351</volume><fpage>2481</fpage><lpage>2488</lpage><pub-id pub-id-type="pmid">15590950</pub-id></citation></ref><ref id="EHN540C23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goldenberg</surname><given-names>I</given-names></name><name><surname>Moss</surname><given-names>AJ</given-names></name><name><surname>Hall</surname><given-names>WJ</given-names></name><name><surname>McNitt</surname><given-names>S</given-names></name><name><surname>Zareba</surname><given-names>W</given-names></name><name><surname>Andrews</surname><given-names>ML</given-names></name><name><surname>Cannom</surname><given-names>DS</given-names></name></person-group><article-title>Causes and consequences of heart failure after prophylactic implantation of a defibrillator in the multicenter automatic defibrillator implantation trial II</article-title><source>Circulation</source><year>2006</year><volume>113</volume><fpage>2810</fpage><lpage>2817</lpage><pub-id pub-id-type="pmid">16769917</pub-id></citation></ref><ref id="EHN540C24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wichterle</surname><given-names>D</given-names></name><name><surname>Melenovsky</surname><given-names>V</given-names></name><name><surname>Simek</surname><given-names>J</given-names></name><name><surname>Malik</surname><given-names>J</given-names></name><name><surname>Malik</surname><given-names>M</given-names></name></person-group><article-title>Hemodynamics and autonomic control of heart rate turbulence</article-title><source>J Cardiovasc Electrophysiol</source><year>2006</year><volume>17</volume><fpage>286</fpage><lpage>291</lpage><pub-id pub-id-type="pmid">16643402</pub-id></citation></ref><ref id="EHN540C25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>A</given-names></name><name><surname>Schmidt</surname><given-names>G</given-names></name></person-group><article-title>Last piece of the heart rate turbulence puzzle?</article-title><source>Heart Rhythm</source><year>2007</year><volume>4</volume><fpage>290</fpage><lpage>291</lpage><pub-id pub-id-type="pmid">17341390</pub-id></citation></ref><ref id="EHN540C26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cole</surname><given-names>CR</given-names></name><name><surname>Blackstone</surname><given-names>EH</given-names></name><name><surname>Pashkow</surname><given-names>FJ</given-names></name><name><surname>Snader</surname><given-names>CE</given-names></name><name><surname>Lauer</surname><given-names>MS</given-names></name></person-group><article-title>Heart-rate recovery immediately after exercise as a predictor of mortality</article-title><source>N Engl J Med</source><year>1999</year><volume>341</volume><fpage>1351</fpage><lpage>1357</lpage><pub-id pub-id-type="pmid">10536127</pub-id></citation></ref><ref id="EHN540C27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>LL</given-names></name><name><surname>Kukielka</surname><given-names>M</given-names></name><name><surname>Billman</surname><given-names>GE</given-names></name></person-group><article-title>Heart rate recovery after exercise: a predictor of ventricular fibrillation susceptibility after myocardial infarction</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2005</year><volume>288</volume><fpage>H1763</fpage><lpage>H1769</lpage><pub-id pub-id-type="pmid">15563535</pub-id></citation></ref><ref id="EHN540C28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huikuri</surname><given-names>HV</given-names></name><name><surname>Makikallio</surname><given-names>TH</given-names></name><name><surname>Peng</surname><given-names>CK</given-names></name><name><surname>Goldberger</surname><given-names>AL</given-names></name><name><surname>Hintze</surname><given-names>U</given-names></name><name><surname>Moller</surname><given-names>M</given-names></name></person-group><article-title>Fractal correlation properties of R-R interval dynamics and mortality in patients with depressed left ventricular function after an acute myocardial infarction</article-title><source>Circulation</source><year>2000</year><volume>101</volume><fpage>47</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">10618303</pub-id></citation></ref><ref id="EHN540C29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hohnloser</surname><given-names>SH</given-names></name><name><surname>Ikeda</surname><given-names>T</given-names></name><name><surname>Bloomfield</surname><given-names>DM</given-names></name><name><surname>Dabbous</surname><given-names>OH</given-names></name><name><surname>Cohen</surname><given-names>RJ</given-names></name></person-group><article-title>T-wave alternans negative coronary patients with low ejection and benefit from defibrillator implantation</article-title><source>Lancet</source><year>2003</year><volume>362</volume><fpage>125</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">12867114</pub-id></citation></ref><ref id="EHN540C30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bloomfield</surname><given-names>DM</given-names></name><name><surname>Steinman</surname><given-names>RC</given-names></name><name><surname>Namerow</surname><given-names>PB</given-names></name><name><surname>Parides</surname><given-names>M</given-names></name><name><surname>Davidenko</surname><given-names>J</given-names></name><name><surname>Kaufman</surname><given-names>ES</given-names></name><name><surname>Shinn</surname><given-names>T</given-names></name><name><surname>Curtis</surname><given-names>A</given-names></name><name><surname>Fontaine</surname><given-names>J</given-names></name><name><surname>Holmes</surname><given-names>D</given-names></name><name><surname>Russo</surname><given-names>A</given-names></name><name><surname>Tang</surname><given-names>C</given-names></name><name><surname>Bigger</surname><given-names>JT</given-names><suffix>Jr</suffix></name></person-group><article-title>Microvolt T-wave alternans distinguishes between patients likely and patients not likely to benefit from implanted cardiac defibrillator therapy: a solution to the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II conundrum</article-title><source>Circulation</source><year>2004</year><volume>110</volume><fpage>1885</fpage><lpage>1889</lpage><pub-id pub-id-type="pmid">15451804</pub-id></citation></ref><ref id="EHN540C31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bloomfield</surname><given-names>DM</given-names></name><name><surname>Bigger</surname><given-names>JT</given-names></name><name><surname>Steinman</surname><given-names>RC</given-names></name><name><surname>Namerow</surname><given-names>PB</given-names></name><name><surname>Parides</surname><given-names>MK</given-names></name><name><surname>Curtis</surname><given-names>AB</given-names></name><name><surname>Kaufman</surname><given-names>ES</given-names></name><name><surname>Davidenko</surname><given-names>JM</given-names></name><name><surname>Shinn</surname><given-names>TS</given-names></name><name><surname>Fontaine</surname><given-names>JM</given-names></name></person-group><article-title>Microvolt T-wave alternans and the risk of death or sustained ventricular arrhythmias in patients with left ventricular dysfunction</article-title><source>J Am Coll Cardiol</source><year>2006</year><volume>47</volume><fpage>456</fpage><lpage>463</lpage><pub-id pub-id-type="pmid">16412877</pub-id></citation></ref><ref id="EHN540C32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chow</surname><given-names>T</given-names></name><name><surname>Kereiakes</surname><given-names>DJ</given-names></name><name><surname>Bartone</surname><given-names>C</given-names></name><name><surname>Booth</surname><given-names>T</given-names></name><name><surname>Schloss</surname><given-names>EJ</given-names></name><name><surname>Waller</surname><given-names>T</given-names></name><name><surname>Chung</surname><given-names>ES</given-names></name><name><surname>Menon</surname><given-names>S</given-names></name><name><surname>Nallamothu</surname><given-names>BK</given-names></name><name><surname>Chan</surname><given-names>PS</given-names></name></person-group><article-title>Prognostic utility of microvolt T-wave alternans in risk stratification of patients with ischemic cardiomyopathy</article-title><source>J Am Coll Cardiol</source><year>2006</year><volume>47</volume><fpage>1820</fpage><lpage>1827</lpage><pub-id pub-id-type="pmid">16682307</pub-id></citation></ref><ref id="EHN540C33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmitt</surname><given-names>C</given-names></name><name><surname>Barthel</surname><given-names>P</given-names></name><name><surname>Ndrepepa</surname><given-names>G</given-names></name><name><surname>Schreieck</surname><given-names>J</given-names></name><name><surname>Plewan</surname><given-names>A</given-names></name><name><surname>Schomig</surname><given-names>A</given-names></name><name><surname>Schmidt</surname><given-names>G</given-names></name></person-group><article-title>Value of programmed ventricular stimulation for prophylactic internal cardioverter-defibrillator implantation in postinfarction patients preselected by noninvasive risk stratifiers</article-title><source>J Am Coll Cardiol</source><year>2001</year><volume>37</volume><fpage>1901</fpage><lpage>1907</lpage><pub-id pub-id-type="pmid">11401129</pub-id></citation></ref><ref id="EHN540C34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buxton</surname><given-names>AE</given-names></name><name><surname>Lee</surname><given-names>KL</given-names></name><name><surname>DiCarlo</surname><given-names>L</given-names></name><name><surname>Gold</surname><given-names>MR</given-names></name><name><surname>Greer</surname><given-names>GS</given-names></name><name><surname>Prystowsky</surname><given-names>EN</given-names></name><name><surname>O&#x02019;Toole</surname><given-names>MF</given-names></name><name><surname>Tang</surname><given-names>A</given-names></name><name><surname>Fisher</surname><given-names>JD</given-names></name><name><surname>Coromilas</surname><given-names>J</given-names></name><name><surname>Talajic</surname><given-names>M</given-names></name><name><surname>Hafley</surname><given-names>G</given-names></name></person-group><article-title>Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators</article-title><source>N Engl J Med</source><year>2000</year><volume>342</volume><fpage>1937</fpage><lpage>1945</lpage><pub-id pub-id-type="pmid">10874061</pub-id></citation></ref><ref id="EHN540C35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ikeda</surname><given-names>T</given-names></name><name><surname>Yoshino</surname><given-names>H</given-names></name><name><surname>Sugi</surname><given-names>K</given-names></name><name><surname>Tanno</surname><given-names>K</given-names></name><name><surname>Shimizu</surname><given-names>H</given-names></name><name><surname>Watanabe</surname><given-names>J</given-names></name><name><surname>Kasamaki</surname><given-names>Y</given-names></name><name><surname>Yoshida</surname><given-names>A</given-names></name><name><surname>Kato</surname><given-names>T</given-names></name></person-group><article-title>Predictive value of microvolt T-wave alternans for sudden cardiac death in patients with preserved cardiac function after acute myocardial infarction: results of a collaborative cohort study</article-title><source>J Am Coll Cardiol</source><year>2006</year><volume>48</volume><fpage>2268</fpage><lpage>2274</lpage><pub-id pub-id-type="pmid">17161258</pub-id></citation></ref><ref id="EHN540C36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Exner</surname><given-names>DV</given-names></name><name><surname>Kavanagh</surname><given-names>KM</given-names></name><name><surname>Slawnych</surname><given-names>MP</given-names></name><name><surname>Mitchell</surname><given-names>LB</given-names></name><name><surname>Ramadan</surname><given-names>D</given-names></name><name><surname>Aggarwal</surname><given-names>SG</given-names></name><name><surname>Noullett</surname><given-names>C</given-names></name><name><surname>Van Schaik</surname><given-names>A</given-names></name><name><surname>Mitchell</surname><given-names>RT</given-names></name><name><surname>Shibata</surname><given-names>MA</given-names></name><name><surname>Gulamhussein</surname><given-names>S</given-names></name><name><surname>McMeekin</surname><given-names>J</given-names></name><name><surname>Tymchak</surname><given-names>W</given-names></name><name><surname>Schnell</surname><given-names>G</given-names></name><name><surname>Gillis</surname><given-names>AM</given-names></name><name><surname>Sheldon</surname><given-names>RS</given-names></name><name><surname>Fick</surname><given-names>GH</given-names></name><name><surname>Duff</surname><given-names>HJ</given-names></name></person-group><article-title>Noninvasive risk assessment early after a myocardial infarction the REFINE study</article-title><source>J Am Coll Cardiol</source><year>2007</year><volume>50</volume><fpage>2275</fpage><lpage>2284</lpage><pub-id pub-id-type="pmid">18068035</pub-id></citation></ref><ref id="EHN540C37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>La Rovere</surname><given-names>MT</given-names></name><name><surname>Bigger</surname><given-names>JT</given-names><suffix>Jr</suffix></name><name><surname>Marcus</surname><given-names>FI</given-names></name><name><surname>Mortara</surname><given-names>A</given-names></name><name><surname>Schwartz</surname><given-names>PJ</given-names></name></person-group><article-title>Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators</article-title><source>Lancet</source><year>1998</year><volume>351</volume><fpage>478</fpage><lpage>484</lpage><pub-id pub-id-type="pmid">9482439</pub-id></citation></ref><ref id="EHN540C38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>OD</given-names></name><name><surname>Abildstrom</surname><given-names>SZ</given-names></name><name><surname>Ottesen</surname><given-names>MM</given-names></name><name><surname>Rask-Madsen</surname><given-names>C</given-names></name><name><surname>Bagger</surname><given-names>H</given-names></name><name><surname>Kober</surname><given-names>L</given-names></name><name><surname>Torp-Pedersen</surname><given-names>C</given-names></name></person-group><article-title>Increased risk of sudden and non-sudden cardiovascular death in patients with atrial fibrillation/flutter following acute myocardial infarction</article-title><source>Eur Heart J</source><year>2006</year><volume>27</volume><fpage>290</fpage><lpage>295</lpage><pub-id pub-id-type="pmid">16267070</pub-id></citation></ref><ref id="EHN540C39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sade</surname><given-names>E</given-names></name><name><surname>Aytemir</surname><given-names>K</given-names></name><name><surname>Oto</surname><given-names>A</given-names></name><name><surname>Nazli</surname><given-names>N</given-names></name><name><surname>Ozmen</surname><given-names>F</given-names></name><name><surname>Ozkutlu</surname><given-names>H</given-names></name><name><surname>Tokgozoglu</surname><given-names>L</given-names></name><name><surname>Aksoyek</surname><given-names>S</given-names></name><name><surname>Ovunc</surname><given-names>K</given-names></name><name><surname>Kabakci</surname><given-names>G</given-names></name><name><surname>Ozer</surname><given-names>N</given-names></name><name><surname>Kes</surname><given-names>S</given-names></name></person-group><article-title>Assessment of heart rate turbulence in the acute phase of myocardial infarction for long-term prognosis</article-title><source>Pacing Clin Electrophysiol</source><year>2003</year><volume>26</volume><fpage>544</fpage><lpage>550</lpage><pub-id pub-id-type="pmid">12710312</pub-id></citation></ref><ref id="EHN540C40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jokinen</surname><given-names>V</given-names></name><name><surname>Tapanainen</surname><given-names>JM</given-names></name><name><surname>Seppanen</surname><given-names>T</given-names></name><name><surname>Huikuri</surname><given-names>HV</given-names></name></person-group><article-title>Temporal changes and prognostic significance of measures of heart rate dynamics after acute myocardial infarction in the beta-blocking era</article-title><source>Am J Cardiol</source><year>2003</year><volume>92</volume><fpage>907</fpage><lpage>912</lpage><pub-id pub-id-type="pmid">14556864</pub-id></citation></ref></ref-list></back></article>